Cargando…

A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma

BACKGROUND: Knowledge of the prevalence of thromboemboli and the associated hemostatic status in dogs with carcinoma or sarcoma is unknown and might allow earlier intervention. OBJECTIVES: Estimate prevalence of thromboemboli and their association with hemostatic changes in dogs with carcinomas or s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pazzi, Paolo, Fosgate, Geoffrey T., Rixon, Anouska, Hanekom, Josef, Kristensen, Annemarie T., Goddard, Amelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473004/
https://www.ncbi.nlm.nih.gov/pubmed/37548637
http://dx.doi.org/10.1111/jvim.16828
_version_ 1785100187899789312
author Pazzi, Paolo
Fosgate, Geoffrey T.
Rixon, Anouska
Hanekom, Josef
Kristensen, Annemarie T.
Goddard, Amelia
author_facet Pazzi, Paolo
Fosgate, Geoffrey T.
Rixon, Anouska
Hanekom, Josef
Kristensen, Annemarie T.
Goddard, Amelia
author_sort Pazzi, Paolo
collection PubMed
description BACKGROUND: Knowledge of the prevalence of thromboemboli and the associated hemostatic status in dogs with carcinoma or sarcoma is unknown and might allow earlier intervention. OBJECTIVES: Estimate prevalence of thromboemboli and their association with hemostatic changes in dogs with carcinomas or sarcomas; estimate predictive values of hemostatic variables for thromboembolic disease in tumor‐bearing dogs. ANIMALS: Thirty‐two dogs with sarcoma, 30 with carcinoma, 20 healthy age‐controlled dogs. METHODS: Prospective cross‐sectional study. A hemostasis panel (platelet concentration, thromboelastography, fibrinogen and D‐dimer concentration, factor X, VII and antithrombin activity) was performed in all dogs. Tumor‐bearing dogs underwent complete post mortem and histopathological evaluation. Comparisons between healthy dogs and tumor‐bearing dogs with and without intracavitary hemorrhage; and tumor‐bearing dogs with and without microthrombi were analyzed. RESULTS: Thromboembolic disease was identified in 32/62 (52%, 95% CI: 39%‐65%) tumor‐bearing dogs. Microthrombi were identified in 31/62 (50%, 95% CI: 37%‐63%) dogs, 21/31 (68%, 95% CI: 49%‐83%) had exclusively intra‐tumoral microthrombi, 10/31 (32%, 95% CI: 17%‐51%) had distant microthrombi. Macrothrombi were identified in 3 tumor‐bearing dogs. Hemostatic changes potentially consistent with overt and non‐overt disseminated intravascular coagulation were identified in some tumor‐bearing dogs. D‐dimer concentrations were significantly higher (P = .02) and platelet concentration significantly lower (P = .03) in tumor‐bearing dogs with microthrombi compared to tumor‐bearing dogs without microthrombi. D‐dimer concentration above 500 ng/mL was 80% sensitive and 41% specific for the prediction of microthrombi presence. CONCLUSION: The high microthrombi prevalence and concomitant hemostatic dysfunction in dogs with carcinomas or sarcomas has not previously been reported, though the clinical importance is unknown. Increased D‐dimer concentration might increase suspicion of microthrombi.
format Online
Article
Text
id pubmed-10473004
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-104730042023-09-02 A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma Pazzi, Paolo Fosgate, Geoffrey T. Rixon, Anouska Hanekom, Josef Kristensen, Annemarie T. Goddard, Amelia J Vet Intern Med SMALL ANIMAL BACKGROUND: Knowledge of the prevalence of thromboemboli and the associated hemostatic status in dogs with carcinoma or sarcoma is unknown and might allow earlier intervention. OBJECTIVES: Estimate prevalence of thromboemboli and their association with hemostatic changes in dogs with carcinomas or sarcomas; estimate predictive values of hemostatic variables for thromboembolic disease in tumor‐bearing dogs. ANIMALS: Thirty‐two dogs with sarcoma, 30 with carcinoma, 20 healthy age‐controlled dogs. METHODS: Prospective cross‐sectional study. A hemostasis panel (platelet concentration, thromboelastography, fibrinogen and D‐dimer concentration, factor X, VII and antithrombin activity) was performed in all dogs. Tumor‐bearing dogs underwent complete post mortem and histopathological evaluation. Comparisons between healthy dogs and tumor‐bearing dogs with and without intracavitary hemorrhage; and tumor‐bearing dogs with and without microthrombi were analyzed. RESULTS: Thromboembolic disease was identified in 32/62 (52%, 95% CI: 39%‐65%) tumor‐bearing dogs. Microthrombi were identified in 31/62 (50%, 95% CI: 37%‐63%) dogs, 21/31 (68%, 95% CI: 49%‐83%) had exclusively intra‐tumoral microthrombi, 10/31 (32%, 95% CI: 17%‐51%) had distant microthrombi. Macrothrombi were identified in 3 tumor‐bearing dogs. Hemostatic changes potentially consistent with overt and non‐overt disseminated intravascular coagulation were identified in some tumor‐bearing dogs. D‐dimer concentrations were significantly higher (P = .02) and platelet concentration significantly lower (P = .03) in tumor‐bearing dogs with microthrombi compared to tumor‐bearing dogs without microthrombi. D‐dimer concentration above 500 ng/mL was 80% sensitive and 41% specific for the prediction of microthrombi presence. CONCLUSION: The high microthrombi prevalence and concomitant hemostatic dysfunction in dogs with carcinomas or sarcomas has not previously been reported, though the clinical importance is unknown. Increased D‐dimer concentration might increase suspicion of microthrombi. John Wiley & Sons, Inc. 2023-08-07 /pmc/articles/PMC10473004/ /pubmed/37548637 http://dx.doi.org/10.1111/jvim.16828 Text en © 2023 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle SMALL ANIMAL
Pazzi, Paolo
Fosgate, Geoffrey T.
Rixon, Anouska
Hanekom, Josef
Kristensen, Annemarie T.
Goddard, Amelia
A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma
title A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma
title_full A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma
title_fullStr A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma
title_full_unstemmed A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma
title_short A prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma
title_sort prospective evaluation of the prevalence of thromboemboli and associated hemostatic dysfunction in dogs with carcinoma or sarcoma
topic SMALL ANIMAL
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473004/
https://www.ncbi.nlm.nih.gov/pubmed/37548637
http://dx.doi.org/10.1111/jvim.16828
work_keys_str_mv AT pazzipaolo aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT fosgategeoffreyt aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT rixonanouska aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT hanekomjosef aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT kristensenannemariet aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT goddardamelia aprospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT pazzipaolo prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT fosgategeoffreyt prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT rixonanouska prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT hanekomjosef prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT kristensenannemariet prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma
AT goddardamelia prospectiveevaluationoftheprevalenceofthromboemboliandassociatedhemostaticdysfunctionindogswithcarcinomaorsarcoma